Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wednesday.

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the earlier stages of Alzheimer’s disease as compared to the condition’s natural progression.

There is progress to report in the battle against Alzheimer's. While there is still no cure, new tests and new treatments are presenting more options. Dr. Jon LaPook reports.

Research will now examine whether the drug should be given to those without any symptoms in order to prevent the disease. Results presented at the Alzheimer’s Association International Conference in Toronto found the “game-changing” treatment can clear the devastating plaques associated with Alzheimer’s far more rapidly than any current licensed drug.